← SynDRA
ZOLEDRONIC ACID ANHYDROUS
SynDRA canonical compound SYN0002579 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | FDPS |
|---|
| Mechanism of action | Farnesyl pyrophosphate synthase inhibitor |
|---|
| Indication | Paget's disease |
|---|
| Disease area | endocrinology |
|---|
All known targets
- FDPS
- GGPS1
- BTN3A1
- BTS1
- CA12
- CA14
- CA2
- CA9
- FPPS
- Fdps
- MMP14
- MMP2
Mechanisms of action (all sources)
- Osteoclast inhibitor
- Bone resorption inhibitor
- Metalloproteinase inhibitor
- Farnesyl pyrophosphate synthase inhibitor
- FDPS INHIBITOR
- Farnesyl diphosphate synthase inhibitor
- PLK1 INHIBITOR
- FDPS MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Bone Density Conservation Agents
ATC classes
- M05B · DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Cross-references
Synonyms
- RECLAST
- Reclast
- ZOLEDRONIC
- ZOLEDRONIC ACID
- ZOMETA
- zoledronic acid
- zoledronate
- zoledronic acid monohydrate
- zometa
- zoledronic acid hydrate
- Anhydrous zoledronic acid
- Zoledronate
- Aclasta
- ZOL
- Zometa
- Novartis brand of zoledronic acid
- Zoledronic acid
- Zometa Concentrate
- Bisphosphonate 3
- CGP-42446
- CGP 42446A
- Aclasta (TN)
- CGP-42'446
- KS-1132
- Reclast (TN)
- Zoledronic acid (INN)
- Zoledronic acid [USAN:INN]
- Zomera (TN)
- Zometa (Novartis)
- Zometa (TN)
- Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
- zoledronic-acid
- Zoledronate hydrate
- Zoledronic acid hydrate
- Anhydrous Zoledronic Acid
- Zoladrona acid mylan
- ZOLEDRONIC ACID TEVA GENERICS
- zoledronic acid monohydrate (ep monograph)
- NSC 721517
Look up ZOLEDRONIC ACID ANHYDROUS in the interactive SynDRA portal →